U.S. Markets close in 2 hrs 40 mins

Nuo Therapeutics, Inc. (AURX)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.00010.0000 (0.00%)
As of 03:30PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0001
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0001 - 0.0001
52 Week Range0.0001 - 1.2200
Avg. Volume404
Market Cap2,372
Beta (5Y Monthly)4.81
PE Ratio (TTM)N/A
EPS (TTM)-0.0410
Earnings DateAug 17, 2020 - Aug 21, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    Nuo Therapeutics Announces Publication of Final Decision Memo for Autologous Blood Derived Products for Chronic Non-Healing Wounds by Centers for Medicare & Medicaid Services

    Nuo Therapeutics, Inc. (OTC Pink: AURX) ("Nuo" or the "Company"), today announced the recent publication of the final decision memo for Autologous Blood-Derived Products for Chronic Non-Healing Wounds (CAG-00190R4). On April 13, 2021, Centers for Medicare & Medicaid Services (CMS) concluded in its final coverage decision memo (available at the URL at the bottom of this release) that Medicare will cover autologous platelet-rich plasma (PRP) for treatment of chronic non-healing diabetic wounds (DFUs) under section 1862(a)(1)(A) of the Social Security Act. This final decision follows the favorable proposed decision memo which was published December 21, 2020 and followed by a thirty-day public comment period. In its final decision memo, CMS concluded that the coverage for DFUs would be for a duration of 20 weeks and limited to devices whose FDA cleared indications include the management of exuding cutaneous wounds such as DFUs. Coverage of autologous PRP beyond 20 weeks for DFUs and for the treatment of all chronic, non-healing wounds will be determined by local Medicare Administrative Contractors (MACs).